Abstract Details

Title Monitoring Adherence in Multiple Sclerosis Using the Electronic Self-Injection Device RebiSmartTM: Interim Results of a Noninterventional Study in Patients in Germany (READOUTsmart)

Topic MS and Related Diseases

Presentation(s) P01 - (-)

Poster/Presentation
Number 166

Objective

Background BACKGROUND: Active RMS requires long-term treatment with disease-modifying drugs, which are commonly administered by self-injection. Injection-related issues can affect patient adherence. RebiSmartTM is an electronic autoinjector for the administration of sc IFN ?-1a that simplifies the injection process and allows objective adherence monitoring through an electronic dosing log.

Design/Methods DESIGN/METHODS: READOUTsmart is a 24-month noninterventional, multicenter, German study conducted in patients with CIS or RMS (aged 12-65 years) prescribed sc IFN ?-1a (44 or 22 [mu]g three times weekly) administered with RebiSmartTM. Quantitative adherence was measured as the percentage of prescribed injections (as recorded by RebiSmartTM), and qualitative adherence as the percentage of weeks with three evenly distributed injections with correct preceding intervals. Here we report results of an interim analysis at Month 3.

Results RESULTS: A total of 265 patients participated in the study; 84 had complete 3-month data available and were included in this analysis. Of these, 66 (78.6%) were female; the mean (standard deviation; SD) age was 38.7 (11.0) years, and mean (SD) disease duration 4.1 (6.5) years. Out of 36 prescribed injections, mean (SD) quantitative adherence at Month 3 was 97.4% (10.8%); 65 (77.4%) patients achieved 100% adherence, and 71 (84.5%) patients achieved ?95% adherence. The mean (SD) number of injections per patient was 35.1 (3.9); 16 (19.0%) patients missed 1-4 injections, and 3 (3.6%) missed >4 injections. Mean (SD) qualitative adherence was 71.7% (26.7%).

Conclusions CONCLUSIONS: Administration of sc IFN ?-1a using RebiSmartTM was associated with high quantitative adherence over 3 months. Moreover, the RebiSmartTM data retrieval function can help physicians detect dosing regimen deviations and aid objective patient-physician discussions regarding adherence issues.

Authors/Disclosures
Peter Rieckmann, MD, FAAN (Direktor Neurologische Klinik) PRESENTER	No disclosure on file
	No disclosure on file
Matthias Schwab, PhD (Klinik f.Neurol.u.Psychiatrie)	No disclosure on file
Dieter Poehlau, MD (Neurologische Abteilung)	No disclosure on file
Torsten Wagner (Merck Serono GmbH)	No disclosure on file
Antonios Bayas	No disclosure on file

��ɫ��

��ɫ��